Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.

J Hematol Oncol · 2018 · PMC5793409 · PMID 29386069

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Because it showed a trend toward improved outcomes in APC patients without KRAS mutations (ORR 48%; mOS, 18.2 months), refametinib in combination with gemcitabine is especially encouraged when patients harbored KRAS mutations.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.